Vericel (VCEL) Gains from Investment Securities (2010 - 2026)
Vericel's (VCEL) quarterly Gains from Investment Securities came in at -$21000.0 in Q1 2026, down 100.34% year-on-year from $6.2 million in Q1 2025, and down 162.5% quarter-over-quarter from -$8000.0 in Q4 2025.
Vericel (VCEL) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Vericel has disclosed Gains from Investment Securities across 17 years of filings, most recently posting -$21000.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$21000.0, down 100.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.2 million (down 228.57% YoY), and the FY2024 annual result was $628000.0, down 73.17% from the prior year.
- Gains from Investment Securities came in at -$21000.0 for Q1 2026 at Vericel, down from -$8000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $6.2 million in Q1 2025 to a low of -$6.2 million in Q2 2025.
- The 5-year median for Gains from Investment Securities is $17000.0 (2025), against an average of $172117.6.
- Across the five-year window, Gains from Investment Securities slumped 2798.08% in 2022 and soared 20200.0% in 2024, its largest moves.
- Vericel's Gains from Investment Securities stood at -$1.5 million in 2022, then surged by 256.54% to $2.4 million in 2023, then sank by 210.64% to -$2.6 million in 2024, then surged by 99.69% to -$8000.0 in 2025, then slumped by 162.5% to -$21000.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$21000.0 (Q1 2026), -$8000.0 (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21,000.00 |
| Mar 31, 2026 | -21,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -6.22 Mn |
| Jun 30, 2025 | -6.22 Mn |
| Mar 31, 2025 | 6.21 Mn |
| Mar 31, 2025 | 6.21 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | 201,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Jun 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.36 Mn |
| Dec 31, 2023 | 2.36 Mn |